Corrigendum: CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder.

MLA

Martucci, Cataldo, et al. “Corrigendum: CHF6297: A Novel Potent and Selective P38 MAPK Inhibitor with Robust Anti-Inflammatory Activity and Suitable for Inhaled Pulmonary Administration as Dry Powder.” Frontiers in Pharmacology, Nov. 2024, pp. 1–2. EBSCOhost, https://doi.org/10.3389/fphar.2024.1497520.

APA

Martucci, C., Allen, A. D., Moretto, N., Bagnacani, V., Fioni, A., Patacchini, R., Civelli, M., Villetti, G., & Facchinetti, F. (2024). Corrigendum: CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder. Frontiers in Pharmacology, 1–2. https://doi.org/10.3389/fphar.2024.1497520

Chicago

Martucci, Cataldo, Andrew Dennis Allen, Nadia Moretto, Valentina Bagnacani, Alessandro Fioni, Riccardo Patacchini, Maurizio Civelli, Gino Villetti, and Fabrizio Facchinetti. 2024. “Corrigendum: CHF6297: A Novel Potent and Selective P38 MAPK Inhibitor with Robust Anti-Inflammatory Activity and Suitable for Inhaled Pulmonary Administration as Dry Powder.” Frontiers in Pharmacology, November, 1–2. doi:10.3389/fphar.2024.1497520.